Glycogen Storage Disorders (GSD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Glycogen Storage Disorders (GSD) – Drugs In Development, 2024 report and make more profitable business decisions.
Glycogen storage diseases (GSDs) constitute inherited inborn errors in carbohydrate metabolism, with clinical manifestations emerging from neonatal stages to adulthood. Typically, these disorders arise from deficiencies in specific enzymes crucial for glycogen breakdown, leading to abnormal glycogen accumulation in the liver or skeletal muscles. The incapacity to mobilize glucose from glycogen results in hypoglycemia and exercise-induced weakness, contributing to enduring complications. The intricate nature of these metabolic disruptions underscores the importance of understanding GSDs for timely diagnosis and management, addressing both immediate symptoms such as hypoglycemia, and long-term consequences like exercise-induced weakness.
The Glycogen Storage Disorders (GSD) drugs in development market research report provide comprehensive information on the therapeutics under development for Glycogen Storage Disorders (GSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glycogen Storage Disorders (GSD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Glycogen Storage Disorders (GSD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Glycogen Storage Disorders (GSD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Glycogen Storage Disorders (GSD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Glycogen Storage Disorders (GSD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alexion Pharmaceuticals IncBeam Therapeutics Inc
Boehringer Ingelheim International GmbH
Daiichi Sankyo Co Ltd
Golden Heart Flower Ltd
Kriya Therapeutics Inc
Liberyx Therapeutics Ltd
Moderna Inc
Orpha Labs
Papillon Therapeutics Inc
Prime Medicine Inc
Reneo Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
Shanghai Pharmaceuticals Holding Co Ltd
Soleno Therapeutics Inc
Taysha Gene Therapies Inc
Ultragenyx Pharmaceutical Inc
University of California San Diego
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Glycogen Storage Disorders (GSD) reports